The Disease Forecasting Company.
Airfinity is bringing together some of the leading experts across the life science space for an exclusive roundtable on the role of forecasting in improving disease outcomes and the strategies needed to reduce disease burden.
Read More →STAT | May 26, 2023
Bird Flu Detectives Seek Clues to Next Global PandemicBloomberg | May 2, 2023
Will your health plan cover new obesity drugs?Bloomberg | Apr 27, 2023
Disease forecasters are convinced there’s a 27% chance of another COVID-like pandemic within 10 years—but experts believe there’s a silver bulletFortune | Apr 18, 2023
View All →
What's happening in a given disease area?
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Identify the true need for a vaccine or a treatment.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
Maximise impact to save lives
Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.
OUR PLATFORM:
New science
Market & Production
Policies
Disease & Prevalence
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
Director General,
IFPMA
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,
The Economist